Furthermore, we demonstrated that TGI1002 is able to overcome multi-drug resistant CML with BCR-ABLT315I mutation through disrupting the interaction between SET and PP2A. This evidence concerns the gene PTPA and chronic myelogenous leukemia, BCR-ABL1 positive.